Research location

Dijon

France

Published trials833

Site observations879

Linked trials published833

Page1 / 17

Research activity in Dijon

France

CureCurrent currently publishes aggregate city-level research activity for this location: 833 trials and 879 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Dijon

833 linked trials · page 1 of 17

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast CancerNCT07701941 · 2026-09-17 · 1 site observation

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes MellitusNCT07784725 · 2026-08-19 · 1 site observation

Skipping Hormone Therapy in Low-Risk Early Breast CancerNCT07661927 · 2026-07-06 · 1 site observation

Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic TestsNCT07106632 · 2026-06-26 · 1 site observation

Efficacy of 12-week Daytime Restricted Eating on Hepatic Steatosis of ObesityNCT07378072 · 2026-06-17 · 1 site observation

Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural MesotheliomaNCT07234058 · 2026-04-02 · 1 site observation

EXOPULSE Suit and Walking Ability of Patients With Multiple SclerosisNCT07252895 · 2026-03-30 · 1 site observation

Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/ResistanceNCT07483983 · 2026-03-25 · 1 site observation

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045 · 2026-03-16 · 1 site observation

Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)NCT07317102 · 2026-03-16 · 2 site observations

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)NCT07361510 · 2026-03-12 · 1 site observation

Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)NCT06937905 · 2026-02-06 · 2 site observations

Stratification of Arrhythmic Risk and/or Heart Failure Risk in Patients With Hereditary Heart DiseaseNCT07257289 · 2026-02-03 · 1 site observation

Home Treatment of Patients With Active Cancer and Acute Pulmonary Embolism Without HESTIA Criteria.NCT07315347 · 2026-02-02 · 1 site observation

Pharmaceutical Management in Targeted Radioligand TherapyNCT07389512 · 2026-01-09 · 1 site observation

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)NCT07174336 · 2025-12-22 · 1 site observation

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant RibociclibNCT07237256 · 2025-12-18 · 1 site observation

Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously TreatedNCT06908993 · 2025-12-09 · 1 site observation

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)NCT06996782 · 2025-11-24 · 1 site observation

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung CancerNCT07001618 · 2025-11-17 · 1 site observation

DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyNCT07472517 · 2025-11-07 · 1 site observation

Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung CancerNCT06656598 · 2025-11-07 · 1 site observation

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerNCT06899126 · 2025-10-24 · 1 site observation

Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI.NCT07195344 · 2025-10-15 · 1 site observation

Arm Swelling Occurence in Breast Cancer Patients With Nodal Radiotherapy: Impact of Informing Them of AI-predicted RiskNCT07187726 · 2025-10-07 · 1 site observation

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) AmyloidosisNCT07207811 · 2025-10-02 · 1 site observation

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)NCT07164443 · 2025-09-02 · 1 site observation

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid TumorsNCT07169734 · 2025-08-26 · 1 site observation

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 · 2025-07-25 · 1 site observation

Health-economic Assessment of Robot-assisted Bariatric SurgeryNCT06858761 · 2025-07-25 · 1 site observation

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)NCT06757634 · 2025-07-24 · 1 site observation

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's DiseaseNCT06976216 · 2025-07-14 · 1 site observation

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 · 2025-06-25 · 1 site observation

Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by BrigatinibNCT06620835 · 2025-06-19 · 1 site observation

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerNCT06868277 · 2025-04-10 · 1 site observation

Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of RelapseNCT06625970 · 2025-04-10 · 1 site observation

Clinical Evaluation of the Medtronic Implantable Insulin Pump System (MIIPS 2020) in Adult Subjects With Type 1 Diabetes (CIP347)NCT06739811 · 2025-03-21 · 1 site observation

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinNCT06677060 · 2025-03-14 · 1 site observation

Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and SurgeryNCT05973864 · 2025-03-11 · 1 site observation

The Effect of Improved Glycemic Control on the Composition and Function of High-Density Lipoproteins (HDL) in Patients With Type 1 DiabetesNCT07564752 · 2025-02-25 · 1 site observation

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World ContextNCT06487078 · 2025-01-20 · 1 site observation

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBCNCT06078384 · 2024-12-27 · 1 site observation

Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVDNCT03593317 · 2024-12-20 · 1 site observation

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid TumorsNCT06747585 · 2024-12-16 · 1 site observation

Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.NCT05879276 · 2024-12-16 · 1 site observation

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.NCT06382948 · 2024-12-05 · 1 site observation

EkiYou-Study-2 : A National Multicentric Trial of the EkiYou Application for Insulin Bolus CalculationNCT06738849 · 2024-11-05 · 1 site observation

Role of High-Throughput Whole Genome Sequencing for the Diagnosis and Care of Atypical DiabetesNCT06570278 · 2024-10-30 · 1 site observation

Type 2 DIAbeTes With NAFLD: innOvative Biomarkers of Disease progressioN and clInical outComesNCT06567990 · 2024-09-25 · 1 site observation

Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)NCT06496581 · 2024-09-12 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.